Anne Richards
Media playback is unsupported on your device

AstraZeneca shareholders question Pfizer deal

UK drugs company AstraZeneca has rejected an improved "final" takeover offer from US drugs giant Pfizer.

Pfizer had made a new offer of £55 per share, valuing AstraZeneca at about £69bn.

Aberdeen Asset Management's Anne Richards told BBC News about some of the shareholders' reaction to the latest bid rejection.

  • 19 May 2014
Go to next video: Cameron 'neutral' over Pfizer bid